TOG Review (RCOG Journal)

MRCOG Part 2

Maternal Medicine

Inflammatory bowel disease in pregnancy

Key Statistics

  • 50% — IBD diagnosed before age 35
  • 2× — RR active disease if active at conception
  • 30% — Relapse risk in pregnancy if quiescent at conception

Don't-miss facts

  1. Key predictors of good outcome: clinical remission at conception + good disease control in pregnancy

  2. Active disease at conception → 2× RR of active disease in pregnancy; quiescent disease → ~30% relapse risk (same as non-pregnant)

  3. UC (not CD): significantly ↑activity during pregnancy (RR 2.19) and postpartum (RR 6.22)

  4. Methotrexate = contraindicated (FDA X); mycophenolate mofetil = avoid; stop ≥3 months pre-conception

  5. Sulfasalazine: max 3 g/day; give 5 mg/day folic acid

  6. Avoid CT in pregnancy; avoid fluoroquinolones; avoid anti-integrins (vedolizumab) where possible

  7. Biologics: discontinue by 30–32 weeks; delay live vaccines in exposed infants until drug undetectable (≥6 months)

  8. Steroids >5 mg prednisolone-equivalent for >4 weeks pre-delivery → hydrocortisone cover at delivery/labour

  9. Avoid episiotomy (perianal disease trigger); planned caesarean for active perianal/rectal disease or post ileo-anal pouch surgery

  10. Postpartum: NSAIDs may worsen IBD; opiates → constipation/worsened perianal disease – co-prescribe osmotic laxatives

Drug safety at a glance

Continue: aminosalicylates, metronidazole, steroids, thiopurines, biologics

Avoid/stop: methotrexate, mycophenolate mofetil, anti-integrins (preferably), fluoroquinolones

Abbreviation Key

  • IBD — inflammatory bowel disease
  • MRI — magnetic resonance imaging
  • CD — Crohn’s disease
  • CT — computed tomography
  • UC — ulcerative colitis
  • ECCO — European Crohn’s and Colitis Organisation
  • NICE — National Institute for Health and Care Excellence
  • TREAT — Therapy Resource Evaluation Assessment Tool registry
  • FDA — US Food and Drug Administration
  • PIANO — Pregnancy in IBD and Neonatal Outcomes registry
  • TNF — tumour necrosis factor
  • GETAID — Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
  • IL — interleukin
  • Fc — fragment crystallisable (placental IgG transfer receptor)

Source: Kapoor A et al. Inflammatory bowel disease in pregnancy. The Obstetrician & Gynaecologist 2016;18:205–212. doi:10.1111/tog.12271

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free